NASDAQ:CLSN
Delisted
Celsion Corporation Stock News
$1.56
+0.0600 (+4.00%)
At Close: Jan 27, 2023
Celsion Corporation Announces Company Name Change to Imunon, Inc.
08:30pm, Monday, 19'th Sep 2022 GlobeNewswire Inc.
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
10:30pm, Monday, 12'th Sep 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Execut
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m.
06:30pm, Monday, 12'th Sep 2022
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executiv
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
01:15pm, Wednesday, 07'th Sep 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief E
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
09:15am, Wednesday, 07'th Sep 2022
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Exe
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
12:30pm, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model
Celsion Corporation's (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript
03:31pm, Monday, 15'th Aug 2022
Celsion Corporation (NASDAQ:CLSN ) Q2 2022 Earnings Conference Call August 15, 2022 11:00 AM ET Company Participants Monique Kosse - IR, LifeSci Advisors Michael Tardugno - Executive Chairman Corinne
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
12:30pm, Monday, 08'th Aug 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, anno
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
08:30am, Monday, 08'th Aug 2022
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, annou
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
12:35pm, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
12:30pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit
Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2022 Results - Earnings Call Transcript
03:26pm, Monday, 16'th May 2022
Celsion Corporation (NASDAQ:CLSN ) Q1 2022 Earnings Conference Call May 16, 2022 11:00 AM ET Company Participants Monique Kosse - Investor Relations Michael Tardugno - Chairman, Chief Executive Office
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
12:30pm, Monday, 09'th May 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, annou
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
08:30am, Monday, 09'th May 2022
LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announ
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress
03:30pm, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus
